Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elinzanetant for menopausal vasomotor symptoms in postmenopausal women
2021-000059-38Phase 3Completed
- Sponsor
- Bayer Consumer Health
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in vasomotor symptoms and menopause comparing Elinzanetant with Placebo (2 arms). Primary endpoint: Mean change in frequency of moderate to severe hot flashes from baseline to Week 12. Started Aug 2021; status: completed.
02
Drugs
elinzanetant
03
Conditions
vasomotor symptomsmenopause
Beyond the preview
Go deeper on 2021-000059-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000059-38.